Question Bank › Conversion calendar in hand

Conversion calendar in hand

Conversion calendar in hand: management narrates the coming year as dated deliveries of business already secured

Calls Tested
443
Answered YES
6
Hit Rate
1.4%
rare by design

Adaptive Biotechnologies Corporation (ADPT) — this company's answers

NO on the Q4 2022 call 2023-02-14 C+
The model's full reasoning — Q4 2022 call → NOThe question asks whether management lays out a timetable of specific conversions—identified pieces of business already secured or in motion, each attached to an approximate time frame—so the forward story reads as a schedule of things turning on. Let me examine the transcript for evidence: 1. MRD business: clonoSEQ clinical volumes grew 51%, launched in DLBCL, signed Epic agreement. Management says DLBCL launch and Epic integration are "back half drivers" for 2023. They expect DLBCL to be a meaningful contributor in the second half of 2023. Epic integration expected in back half of year. 2. Genentech IND acceptance: "the IND acceptance for immune medicine, obviously, a big swing factor toward the end of the year. And that's the biggest swing factor in the fourth quarter." They recognized $7 million of the $10 million upfront on acceptance of that milestone. This is in guidance. 3. MRD milestones: "we anticipate MRD milestones in the mid to high single digit millions" and "milestones in both immune medicine and MRD, which were expected by year-end." 4. Revenue guidance: back half weighted, Q1 lowest. Now, are these "already real" items? The DLBCL launch happened (launched at ASH in December). Epic agreement signed. Genentech IND acceptance is pending—it's a milestone that hasn't been achieved yet, it's expected by year-end. That's contingent on FDA acceptance, which is not yet secured. The MRD milestones—are they secured? They say "we anticipate MRD milestones in the mid to high single digit millions" and "we've got roughly 370 million future milestones... we risk adjust those in our guidance with about a 30% to 50% probability of success." So these are risk-adjusted, not secured. The DLBCL launch and Epic integration are real (launched, signed), and they're expected to contribute in the back half. But are they "already real" in the sense of secured business? The launch is done, the integration is signed. But the contribution depends on adoption, which is still being pursued. The Genentech IND is explicitly contingent on FDA acceptance—that's an approval not yet made. So that doesn't count. The MRD milestones are risk-adjusted with 30-50% probability—those are not secured. So what's left? DLBCL launch (done) and Epic integration (signed). These are real items with timing (back half).

← Back to the full ADPT analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, when management talks about the company's NEXT FOUR OR SO QUARTERS, does it lay out a TIMETABLE OF SPECIFIC CONVERSIONS \u2014 identified pieces of business that are ALREADY SECURED OR ALREADY IN MOTION, each attached to an at-least-approximate time frame in which it starts contributing \u2014 so that the forward story reads as a schedule of things turning on, rather than as hopes about demand?\n\nAnswer YES when management's own words convey BOTH of the following as one coherent forward account, in whatever form fits the business:\n\n(1) THE ITEMS ON THE TIMETABLE ARE ALREADY REAL. Management identifies concrete business whose existence is no longer in question \u2014 already won, signed, awarded, ordered, booked, contracted, built, launched, closed, or already ramping \u2014 in whatever form fits the industry: contracted work or orders scheduled for delivery; a facility, capacity, product, service, or location recently completed or opening on a stated timetable and now filling; customers or programs already signed that go live or scale on a described schedule; an acquisition or expansion already closed whose contribution phases in; committed volumes stepping up on agreed dates. One substantial item or several smaller ones together both count. Items still being pursued, negotiated, piloted without commitment, or awaiting approvals, financing, or customer decisions do NOT count toward the timetable.\n\n(2) MANAGEMENT ATTACHES TIMING AND TREATS THE SCHEDULE AS THE FORWARD STORY. Management gives each identified item an at-least-rough time anchor within roughly the coming year (this quarter, next quarter, by mid-year, second half, a named month or season) and presents working through this sequence \u2014 starting, ramping, delivering, onboarding, filling \u2014 as the main driver of where the company's results go from here, conveying directly or plainly in substance that the period just reported does not yet meaningfully reflect these contributions, so today's numbers describe the company before the scheduled conversions land.\n\nAnswer NO if the forward discussion rests mainly on demand strength, market conditions, pipeline, opportunities being pursued, or general optimism, with no dated schedule of secured items. NO if the timetable consists of routine, ordinary-course activity at the company's usual scale \u2014 the normal cadence of openings, orders, or seasonal work it always has \u2014 that management does not present as stepping the company beyond its current level. NO if the named items are contingent on approvals, financing, negotiations, or decisions not yet made, or if the only timing given is vague ('over time', 'in the coming years', 'eventually'). NO if the scheduled items' contributions are already substantially reflected in the reported results. NO if management is chiefly explaining delays, slippage, cancellations, or problems with a previously described schedule. NO if the schedule is assembled only in an analyst's question or model that management does not itself adopt.\n\nUse only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
ESEA Euroseas Ltd. Q4 2022 2023-02-15 C+
SOL ReneSola Ltd Q3 2022 2022-12-01 C+
FLL Full House Resorts, Inc. Q3 2022 2022-11-07 B
FAT FAT Brands Inc. Q4 2021 2022-03-21 F
CPK Chesapeake Utilities Corporation Q3 2017 2017-11-10 A
ESE ESCO Technologies Inc. Q2 2016 2016-05-03 A

How the model reasoned

CPK · Q3 2017 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured business and approximate time frames.
SOL · Q3 2022 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured items and approximate time frames.
FLL · Q3 2022 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured items and approximate time frames.

More from the question bank

Betting on a customer they cannot yet nameGround-level proof points accumulatingWinning more per swing than they used to — aFresh order-of-magnitude reference changeThis quarter could not have been described lOutside actors already movingAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.